Since its outbreak, coronavirus (COVID-19) has cast an unprecedented impact that has reverberated throughout the world. Scientists, government officials, and doctors have searched frantically for a remedy, to help contain further disruption.
In this video, GIOSTAR Co-Founder and Chairman Dr. Anand Srivastava reports on a study examining the potential application of stem cell therapy to help manage the symptoms of this pandemic. The study – entitled Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia – was conducted by a coalition of researchers from China, Spain, India, Italy, and the United States. The team evaluated the prognosis of seven patients suffering from COVID-19 pneumonia after receiving injections of mesenchymal stem cells (MSCs) – recognized widely for their immunomodulatory function.
The study found the following improvements in those subjects after the innovative treatment:
- Alleviation in pneumonia-like symptoms associated with the virus
- Down-regulation (“blocking”) of proinflammatory (bad) cytokines within 3-6 days
- A dramatic increase in the expression of anti-inflammatory (good) cytokines
While additional research is needed to confirm the potential benefits of MSCs on individuals suffering from coronavirus, Dr. Srivastava rightfully indicated that these findings are very encouraging. “It’s wonderful to see the global research community collaborating so closely,” he noted. “It’s through their efforts that we will identify alternative, fast-acting, and comparatively more economical approaches to managing COVID-19 and other severe afflictions impacting the world.”
How Can We Help You?
GIOSTAR has been a pioneer in stem cell therapy and research since its founding 12 years ago. Leveraging more than two decades of groundbreaking research by Co-Founder and Chairman Dr. Anand Srivastava, GIOSTAR has helped thousands of patients suffering from multiple sclerosis, neuropathy, and numerous orthopedic disorders.